BioSpace News Archive

Podium and Poster Presentations to Highlight Initial Findings from Monotherapy Study of Investigational SHP2 Inhibitor, RMC-4630 Additional Poster Presentation to Report New Preclinical Results for Company’s Novel Inhibitors of Oncogenic RAS(ON) mutants

Pre-clinical study seeks to determine the impact of cannabis derivatives on mental health conditions

J.P. Morgan and BofA Securities acted as the exclusive agents to the Company in connection with the Transactions.

Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today outlined key clinical and business priorities for 2020.

Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing treatments for immune-mediated diseases, today announced an expansion in the development of rilzabrutinib (PRN1008) into IgG4-Related Disease (RD).

Ipsen Biopharmaceuticals Canada Inc. today announced the availability of a new delivery system for Somatuline® Autogel® (lanreotide injection) 60, 90, and 120 mg

ArcherDX, Inc., a molecular diagnostics company developing breakthrough solutions to advance and enable the practice of personalized genomic medicine, today announced Mark Massaro has been appointed Chief Financial Officer.

Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a late-stage clinical biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced the appointment of Eldon Mayer as Executive Vice President and Chief Commercial Officer

HeartBeam, Inc., a cardiac diagnostic mHealth company, today announced it has expanded its Board of Directors adding two seasoned professionals, Rich Ferrari, a Silicon Valley venture capitalist and Marga Ortigas-Wedekind, a marketing executive in the cardiac monitoring space.

Cerebral Therapeutics, a clinical-stage pharmaceutical company developing innovative treatments for uncontrolled neurological diseases, announced today a $35 million Series B financing led by RA Capital Management, with participation from additional new investor Perceptive Advisors and existing investors Vivo Capital, LLC and Granite Point Capital Management, L.P.